Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer

Cancer Research

Volumn 75, Issue 7, 2015, Pages 1527-1536

  Neskey, David M ^a   Osman, Abdullah A ^b   Ow, Thomas J ^c   Katsonis, Panagiotis ^d   McDonald, Thomas ^e   Hicks, Stephanie C ^f   Hsu, Teng Kuei ^d   Pickering, Curtis R ^b   Ward, Alexandra ^b   Patel, Ameeta ^b   Yordy, John S ^g   Skinner, Heath D ^b   Giri, Uma ^b   Sano, Daisuke ^h   Story, Michael D ^g,i   Beadle, Beth M ^b   El Naggar, Adel K ^b   Kies, Merrill S ^b   William, William N ^b   Caulin, Carlos ^b   Frederick, Mitchell ^b   Kimmel, Marek ^e   Myers, Jeffrey N ^b   Lichtarge, Olivier ^d   more..

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Rice University   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h Department of Otolaryngology Head and Neck Surgery Yokahama University   (Japan)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENOTYPE PHENOTYPE CORRELATION; HEAD AND NECK CANCER; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LOW RISK POPULATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; TP53 GENE; TUMOR INVASION; VALIDATION STUDY; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETICS; GENOMICS; HEAD AND NECK TUMOR; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENOMICS; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MUTATION; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84930967436     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2735     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational land scape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
4. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-7.
5. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database, R16, November 2012. Hum Mutat 2007;28:622-9.
6. Hayes D, Grandis JR, ElNaggar A. Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research.
7. Erber R CC, Homann N, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998:1671-79.
8. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survivalinsquamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61.
9. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-6.
10. Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, Buijze M, Bloemena E, Snijders PJ, et al. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2011;17: 3733-41.
11. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nature Genetics 2014.
12. Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004;23:2330-8.
13. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-13.
14. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nat Genetics 1993;4:42-6.
15. Muller PA, Vousden KH. p53 mutations in cancer. Nat CellBiol 2013;15:2-8.
16. Xie TX, Zhou G, Zhao M, Sano D, Jasser SA, Brennan RG, et al. Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. Laryngoscope 2013;123:1416-23.
17. Lichtarge O, Wilkins A. Evolution: a guide to perturb protein function and networks. Curr Opin Struct Biol 2010;20:351-9.
18. Madabushi S, Yao H, Marsh M, Kristensen DM, Philippi A, Sowa ME, et al. Structural clusters of evolutionary trace residues are statistically significant and common in proteins. J Mol Biol 2002;316:139-54.
19. Erdin S, Ward RM, Venner E, Lichtarge O. Evolutionary trace annotation of protein function in the structural proteome. J Mol Biol 2010; 396:1451-73.
20. Amin SR, Erdin S, Ward RM, Lua RC, Lichtarge O. Prediction and experimental validation of enzyme substrate specificity in protein structures. Proc Natl Acad Sci U S A 2013;110:E4195-202.
21. Katsonis P, Lichtarge O. A formal perturbation equation betweengenotype and phenotype determines the evolutionary action of protein-coding variations on fitness. Genome Res 2014;24:2050-8.
22. Lichtarge O, Bourne H, Cohen F. An evolutionary trace method defines binding surfaces common to protein families. J Mol Biol 1996;257: 342-58.
23. Mihalek I, Res I, Lichtarge O. A family of evolution-entropy hybrid methods for ranking protein residues by importance. J Mol Biol 2004;336: 1265-82.
24. Henikoff S, Henikoff J. Amino acid substitution matrices from protein blocks. Proc Natl Acad SciU S A 1992;89:10915.
25. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data An 1999;30:253-70.
26. Klein JP, Wu JT. Discretizing a continuous covariate in survival studies. In: Balakrishnan N, Rao CR, editors. Handbook of Statistics 23: advances in survival analysis. New York: Elsevier; 2004. p. 27-42.
27. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011;17:7248-64.
28. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 2013;3: 770-81.
29. Sano D, Fooshee DR, Zhao M, Andrews GA, Frederick MJ, Galer C, et al. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head Neck 2011;33:349-58.
30. Sano D, Myers JN. Xenograft models of head and neck cancers. Head Neck Oncol 2009;1:32.
31. Ketcham AS, Wexler H, Minton JP. Experimental study of metastases. JAMA 1966;198:157-64.
32. Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, et al. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol 2014;232:522-33.
33. Katsonis P, Koire A, Wilson SJ, Hsu TK, Lua RC, Wilkins AD, et al. Single nucleotide variations: biological impact and theoretical interpretation. Protein Sci 2014;23:1650-66.
34. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-9.
35. Vikhanskaya F, Lee MK, Mazzoletti M, Broggini M, Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007;35: 2093-104.
36. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005;65: 2108-14.